Sign Up to like & get
recommendations!
1
Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.149
Abstract: Introduction Treatment with chimeric antigen receptor modified T cells targeting CD30 (CD30.CAR-Ts) without lymphodepletion was found to be safe with preliminary efficacy in patients (pts) with relapsed/refractory (r/r) CD30+ lymphomas (Ramos et al., JCI 2017).…
read more here.
Keywords:
benda;
flu;
lymphodepletion;
cd30 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-11-887067
Abstract: Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS)…
read more here.
Keywords:
patients aggressive;
response;
pfs patients;
favorable cytokine ... See more keywords